Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02860780
Title A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Eli Lilly and Company
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | DEU

Additional content available in CKB BOOST